Market Research Report
Ephrin Type B Receptor 4 - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||365798|
|Published||Content info||49 Pages
Delivery time: 1-2 business days
|Ephrin Type B Receptor 4 - Pipeline Review, H1 2020|
|Published: June 30, 2020||Content info: 49 Pages||
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 18.104.22.168) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report Ephrin Type B Receptor 4 - Pipeline Review, H1 2020, outlays comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 126.96.36.199) - Ephrin type-B receptor 4 is a protein encoded by the EPHB4 gene. It binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells which lead to contact dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. It plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. It plays an important role in postnatal blood vessel remodeling, morphogenesis and permeability.
The molecules developed by companies in Phase II stages are 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Infectious Disease which include indications Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Kaposi Sarcoma, Laryngeal Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Malignant Pleural Mesothelioma, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Oral Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Polycystic Kidney Disease, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
Furthermore, this report also reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.